PHARMA
Hidden Deception: How Research Fraud Slowed Alzheimer's Breakthroughs
A deep dive into how scientific misconduct and fraudulent research has impacted Alzheimer's treatment development, affecting millions of patients and their families.
PHARMA
PHARMA
Xanamem: The 'Exercise in a Pill' That Could Transform Alzheimer's Treatment
Alzheimer's drug Xanamem shows promise in clinical trials by targeting brain cortisol levels, with researchers calling it an "exercise in a pill" that could halt disease progression.
PHARMA
CTAD 2024 Shows How We're Rethinking Alzheimer's Treatment
While new drugs offer hope in Alzheimer's treatment, CTAD 2024 reveals why medical breakthroughs alone won't solve the dementia crisis
TREATMENT
Ultra-Processed Foods and GLP-1 Drugs: A Modern Health Conundrum
The interplay between ultra-processed foods and GLP-1 drugs highlights the complex challenges we face in public health. It underscores the need for a multifaceted approach that considers dietary patterns, food industry practices, pharmaceutical interventi
PHARMA
Alzheimer's Treatment Divide: Are We Chasing the Wrong Target?
The recent survey of neurologists regarding new Alzheimer's treatments reveals a significant divide in the medical community. While these new drugs target amyloid plaques in the brain, there's growing concern that this approach may be too little, too late in the fight against Alzheimer's